Commodity Channel Index
|Bid||2.7500 x 900|
|Ask||3.1100 x 900|
|Day's Range||2.8600 - 3.0500|
|52 Week Range||2.2400 - 9.7400|
|Beta (5Y Monthly)||1.77|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Even if it's not a huge purchase, we think it was good to see that Iain Ross, the Independent Chairman of the Board of...
Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we...
James Garner became the CEO of Kazia Therapeutics Limited (ASX:KZA) in 2016. First, this article will compare CEO...
The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share with investors interim data from its ongoing phase II study of GDC-0084 in glioblastoma, the most common and most aggressive form of primary brain cancer. This data is the subject of a poster presentation at the annual meeting of the Society for Neuro-Oncology (SNO), held in Phoenix, AZ from 20 - 24 November 2019.